These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 21562035)

  • 1. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe.
    De Witt Hamer PC; Mir SE; Noske D; Van Noorden CJ; Würdinger T
    Clin Cancer Res; 2011 Jul; 17(13):4200-7. PubMed ID: 21562035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Wee1-like protein kinase to treat cancer.
    Stathis A; Oza A
    Drug News Perspect; 2010 Sep; 23(7):425-9. PubMed ID: 20862394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting WEE1 Kinase in Cancer.
    Matheson CJ; Backos DS; Reigan P
    Trends Pharmacol Sci; 2016 Oct; 37(10):872-881. PubMed ID: 27427153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WEE1 inhibition sensitizes osteosarcoma to radiotherapy.
    PosthumaDeBoer J; Würdinger T; Graat HC; van Beusechem VW; Helder MN; van Royen BJ; Kaspers GJ
    BMC Cancer; 2011 Apr; 11():156. PubMed ID: 21529352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination.
    Krajewska M; Heijink AM; Bisselink YJ; Seinstra RI; Silljé HH; de Vries EG; van Vugt MA
    Oncogene; 2013 Jun; 32(24):3001-8. PubMed ID: 22797065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry.
    Elbæk CR; Petrosius V; Sørensen CS
    Mutat Res; 2020; 819-820():111694. PubMed ID: 32120135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.
    Wang Y; Li J; Booher RN; Kraker A; Lawrence T; Leopold WR; Sun Y
    Cancer Res; 2001 Nov; 61(22):8211-7. PubMed ID: 11719452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WEE1 inhibition and genomic instability in cancer.
    Vriend LE; De Witt Hamer PC; Van Noorden CJ; Würdinger T
    Biochim Biophys Acta; 2013 Dec; 1836(2):227-35. PubMed ID: 23727417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wee1 Kinase: A Potential Target to Overcome Tumor Resistance to Therapy.
    Esposito F; Giuffrida R; Raciti G; Puglisi C; Forte S
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.
    Hirai H; Iwasawa Y; Okada M; Arai T; Nishibata T; Kobayashi M; Kimura T; Kaneko N; Ohtani J; Yamanaka K; Itadani H; Takahashi-Suzuki I; Fukasawa K; Oki H; Nambu T; Jiang J; Sakai T; Arakawa H; Sakamoto T; Sagara T; Yoshizumi T; Mizuarai S; Kotani H
    Mol Cancer Ther; 2009 Nov; 8(11):2992-3000. PubMed ID: 19887545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wee1 kinase as a target for cancer therapy.
    Do K; Doroshow JH; Kummar S
    Cell Cycle; 2013 Oct; 12(19):3159-64. PubMed ID: 24013427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role for Wee1 in inhibition of G2-to-M transition through the cooperation of distinct human papillomavirus type 1 E4 proteins.
    Knight GL; Turnell AS; Roberts S
    J Virol; 2006 Aug; 80(15):7416-26. PubMed ID: 16840322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.
    Carrassa L; Chilà R; Lupi M; Ricci F; Celenza C; Mazzoletti M; Broggini M; Damia G
    Cell Cycle; 2012 Jul; 11(13):2507-17. PubMed ID: 22713237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma.
    Mir SE; De Witt Hamer PC; Krawczyk PM; Balaj L; Claes A; Niers JM; Van Tilborg AA; Zwinderman AH; Geerts D; Kaspers GJ; Peter Vandertop W; Cloos J; Tannous BA; Wesseling P; Aten JA; Noske DP; Van Noorden CJ; Würdinger T
    Cancer Cell; 2010 Sep; 18(3):244-57. PubMed ID: 20832752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorylation and inactivation of the mitotic inhibitor Wee1 by the nim1/cdr1 kinase.
    Parker LL; Walter SA; Young PG; Piwnica-Worms H
    Nature; 1993 Jun; 363(6431):736-8. PubMed ID: 8515817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.
    Aarts M; Sharpe R; Garcia-Murillas I; Gevensleben H; Hurd MS; Shumway SD; Toniatti C; Ashworth A; Turner NC
    Cancer Discov; 2012 Jun; 2(6):524-39. PubMed ID: 22628408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells.
    Mak JP; Man WY; Chow JP; Ma HT; Poon RY
    Oncotarget; 2015 Aug; 6(25):21074-84. PubMed ID: 26025928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.
    Jin J; Fang H; Yang F; Ji W; Guan N; Sun Z; Shi Y; Zhou G; Guan X
    Neoplasia; 2018 May; 20(5):478-488. PubMed ID: 29605721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA damage detection and repair pathways--recent advances with inhibitors of checkpoint kinases in cancer therapy.
    Ashwell S; Zabludoff S
    Clin Cancer Res; 2008 Jul; 14(13):4032-7. PubMed ID: 18593978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
    Guertin AD; Li J; Liu Y; Hurd MS; Schuller AG; Long B; Hirsch HA; Feldman I; Benita Y; Toniatti C; Zawel L; Fawell SE; Gilliland DG; Shumway SD
    Mol Cancer Ther; 2013 Aug; 12(8):1442-52. PubMed ID: 23699655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.